Exhaled Nitric Oxide May Predict Bronchial Hyperreactivity in Patients with Allergic RhinitisCirillo I.a · Ricciardolo F.L.M.b · Medusei G.a · Signori A.c · Ciprandi G.d
aNavy Medical Service, La Spezia, bDivision of Respiratory Disease, Department of Clinical and Biological Sciences, University of Torino, Torino, cHealth Science Department, Genoa University, and dIRCCS-Azienda Ospedaliera Universitaria San Martino, Genoa, Italy
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: Nowadays it is possible to assess airway inflammation by measuring the fractional concentration of exhaled nitric oxide (FeNO) during an office visit and there is international consensus on the testing methodology. The aim of this study was to evaluate whether FeNO measurement may be a predictor of bronchial hyperreactivity (BHR) in patients with allergic rhinitis (AR). Methods: Two hundred eleven patients (196 males, median age 28.5 years) suffering from persistent AR were evaluated. Values for bronchial function (FVC, FEV1, and FEF25–75), bronchial provocation tests (methacholine), exhaled nitric oxide (FeNO), a visual analogue scale for nasal and bronchial symptoms, and sensitization were assessed. Results: A strong and inverse correlation between FeNO levels and BHR severity was found (r = –0.58). FeNO was a predictive factor for BHR, and 37 ppb was found to be the best cutoff (area under the curve 0.90) to define the presence of BHR in patients with AR. Conclusions: This study highlights the relevance of FeNO as a possible predictive marker for BHR in AR patients and underlines the close link between upper and lower airways. Thus, FeNO measurement could be a useful screening tool in identifying subjects with rhinitis at risk of developing asthma.
© 2012 S. Karger AG, Basel
- Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al: Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy 2008;63(suppl 86):8–160.
National Heart, Lung and Blood Institute, National Institutes of Health: Global Initiative for Asthma: Pocket Guide for Asthma Management and Prevention. Bethesda, NIH, 1997, publication No. 96-3659B.
- Ciprandi G, Cirillo I: The lower airway pathology of rhinitis: update review. J Allergy Clin Immunol 2006;118:1105–1109.
- Ciprandi G, Cirillo I, Signori A: Impact of allergic rhinitis on bronchi: an 8-year follow-up study. Am J Rhinol Allergy 2011;25:72–76.
Ciprandi G, Signori A, Tosca MA, Cirillo I: Spirometric abnormalities in patients with allergic rhinitis: indicator of an asthma march? Am J Rhinol Allergy 2011;32:22–28.
- Crapo RO, Casaburi R, Coates AL, et al: Guidelines for methacholine and exercise challenge testing – 1999. Am J Respir Crit Care Med 2000;161:309–329.
- American Thoracic Society, European Respiratory Society: ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005;171:912–930.
- Lim KG, Mottram C: The use of fraction of exhaled nitric oxide in pulmonary practice. Chest 2008;133:1232–1242.
Pendharkar S, Mehta S: The clinical significance of exhaled nitric oxide in asthma. Can Respir J 2008;15:99–106.
- Roadway GW, Chol JY, Hoffman LA, Sethi JM: Exhaled nitric oxide in the diagnosis and management of asthma: clinical implications. Chron Respir Dis 2009;6:19–29.
- Jatakanon A, Lim S, Kharitonov SA, Chung KF, Barnes PJ: Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. Thorax 1998;53:91–95.
- ElHalawani SM, Nam TL, Mahon RT, Amundson DE: Exhaled nitric oxide as a predictor of exercise-induced bronchoconstriction. Chest 2003;124:639–643.
- Berkman N, Avital A, Breuer R, Bardach E, Springer C, Godfrey S: Exhaled nitric oxide in the diagnosis of asthma: comparison with bronchial provocation tests. Thorax 2005;60:383–388.
- Ciprandi G, Tosca MA, Capasso M: Exhaled nitric oxide in children with allergic rhinitis and/or asthma: a relationship with bronchial hyperreactivity. J Asthma 2010;47:1142–1147.
- Ciprandi G, Caimmi S, Marseglia GL, Tosca MA, Cirillo I: Visual analogue scale assessment of respiration might be a surrogate for spirometry in allergic rhinitis. J Biol Regul Homeost Agents 2010;24:103–105.
Skin tests used in type I allergy testing: position paper – Subcommittee on Skin Tests of the European Academy of Allergology and Clinical Immunology. Allergy 1989;44 (suppl 10):1–59.
- Miller MR, Hankinson J, Brusasco V, Burgos R, Casaburi R, Coates R, et al: Standardisation of spirometry. Eur Respir J 2005:26:319–338.
- Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al: Interpretative strategies for lung function tests. Eur Respir J 2005;26:948–968.
- Plaschke PP, Janson C, Norrman E: Onset and remission of allergic rhinitis and asthma and the relationship with atopic sensitization and smoking. Am J Respir Crit Care 2000;162:920–924.
- Ciprandi G, Cirillo I: FEF25–75 may be a marker of bronchial impairment in allergic rhinitis. J Allergy Clin Immunol 2011;127:549–551.
- Aronsson D, Tufvesson E, Biermer L: Allergic rhinitis with or without concomitant asthma: difference in perception of dyspnoea and levels of fractional exhaled nitric oxide. Clin Exp Allergy 2005;35:1457–1461.
- Cordeiro D, Rudolphus A, Snoey E, Braunstahl GL: Utility of nitric oxide for the diagnosis of asthma in an allergy clinic population. Allergy Asthma Proc 2011;32:119–126.
- Tossa P, Paris C, Zmirou-Navier D, Demange V, Acouetey DS, Michaely JP, et al: Increased in exhaled nitric oxide is associated with bronchial hyperresponsiveness among apprentices. Am J Respir Crit Care Med 2010;182:738–744.
- Keen C, Olin AC, Wennergren G, Gustafsson P: Small airway function, exhaled NO and airway hyper-responsiveness in paediatric asthma. Respir Med 2011;105:1476–1484.
- Skiepko R, Zietkowski Z, Tomasiak-Lozowska MM, Tomasiak M, Bodzenta-Lukaszkyk A: Bronchial hyperresponsiveness and airway inflammation in patients with seasonal allergic rhinitis. J Invest Allergol Clin Immunol 2011;21:532–539.
- Silvestri M, Spallarossa D, Battistini E, Brusasco V, Rossi GA: Dissociation between exhaled nitric oxide and hyperresponsiveness in children with mild intermittent asthma. Thorax 2000;55:484–488.
- Quaedvlieg V, Sele J, Henket M, Louis R: Association between asthma control and bronchial hyperresponsiveness and airways inflammation: a cross-sectional study in daily practice. Clin Exp Allergy 2009;39:1822–1829.
- Porsbierg C, Lund KT, Pedersen L, Backer V: Inflammatory subtypes in asthma are related to airway hyperresponsiveness to mannitol and exhaled NO. J Asthma 2009;46:606–612.
- Sverrild A, Porsbierg C, Thomsen SF, Backer V: Airway hyperresponsiveness to mannitol and methacholine and exhaled nitric oxide: a random-sample population study. J Allergy Clin Immunol 2010;126:952–958.
- Manso L, Madero MF, Ruiz-Garcia M, Fernandez-NietoM, Sastre J: Comparison of bronchial hyperresponsiveness to methacholine and adenosine and airway inflammation markers in patients with suspected asthma. J Asthma 2011;48:335–340.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.